{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040581","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.658342+00:00","generated_at":"2026-06-11T21:38:48.871410+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"aTyr Pharma Q2 2023: cash $112M, R&D $9.8M; Phase 3 EFZO-FIT enrolling globally","bullets":["Cash and investments $112.0M as of June 30, 2023; company expects cash runway into 2026.","R&D expenses $9.8M, G&A $3.7M in Q2 2023.","Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolling up to 264 subjects globally.","Phase 2 EFZO-CONNECT study in SSc-ILD expected to start Q3 2023, enrolling 25 patients.","Received European Commission orphan drug designation for efzofitimod in systemic sclerosis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040581","json":"https://secwatch.observer/filing/0000950170-23-040581.json","markdown":"https://secwatch.observer/filing/0000950170-23-040581.md","text":"https://secwatch.observer/filing/0000950170-23-040581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023040581/0000950170-23-040581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023040581/life-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:38:48.871410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d2682c280fe2eee46a7b34da96dd65fdd939acf","claim":"aTYR PHARMA INC reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023040581/0000950170-23-040581-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}